|
1
|
Dobbie JW: Ultrastructure and pathology of
the peritoneal dialysis. The Textbook of Peritoneal Dialysis. Gokal
R and Nolph KD: 3rd edition. Kluwer Academic Publishers; New York,
NY: pp. 17–44. 1994, View Article : Google Scholar
|
|
2
|
Dobbie JW: Peritoneal ultrastructure and
changes with continuous ambulatory peritoneal dialysis. Perit Dial
Int. 13(Suppl 2): S585–S587. 1993.PubMed/NCBI
|
|
3
|
Chan TM, Leung JK, Tsang RC, Liu ZH, Li LS
and Yung S: Emodin ameliorates glucose- induced matrix synthesis in
human peritoneal mesothelial cells. Kidney Int. 64:519–533. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Katsutani M, Ito T, Masaki T, Kohno N and
Yorioka N: Glucose-based PD solution, but not icodextrin-based PD
solution, induces plasminogen activator inhibitor-1 and tissue-type
plasminogen activator in human peritoneal mesothelial cells via
ERK1/2. Ther Apher Dial. 11:94–100. 2007. View Article : Google Scholar
|
|
5
|
Brown JD and Plutzky J: Peroxisome
proliferator-activated receptors as transcriptional nodal points
and therapeutic targets. Circulation. 115:518–533. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zafiriou S, Stanners SR, Polhill TS,
Poronnik P and Pollock CA: Pioglitazone increases renal tubular
cell albumin uptake but limits proinflammatory and fibrotic
responses. Kidney Int. 65:1647–1653. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ko GJ, Kang YS, Han SY, Lee MH, Song HK,
Han KH, Kim HK, Han JY and Cha DR: Pioglitazone attenuates diabetic
nephropathy through an anti-inflammatory mechanism in type 2
diabetic rats. Nephrol Dial Transplant. 23:2750–2760. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Panchapakesan U, Sumual S, Pollock CA and
Chen X: PPARgamma agonists exert antifibrotic effects in renal
tubular cells exposed to high glucose. Am J Physiol Renal Physiol.
289:F1153–F1158. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma LJ, Marcantoni C, Linton MF, Fazio S
and Fogo AB: Peroxisome proliferator-activated receptor-gamma
agonist troglitazone protects against nondiabetic
glomerulosclerosis in rats. Kidney Int. 59:1899–1910. 2001.
View Article : Google Scholar
|
|
10
|
Peng Y, Liu H, Liu F, Liu Y, Li J and Chen
X: Troglitazone inhibits synthesis of transforming growth
factor-beta1 and reduces matrix production in human peritoneal
mesothelial cells. Nephrology (Carlton). 11:516–523. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang YF, Yang X, Zhang YJ, Sun YL, Zou
XL, Kong QY, Dong XQ, Ye XQ and Yu XQ: Peroxisome
proliferator-activated receptor-gamma is expressed by rat
peritoneal mesothelial cells: its potential role in peritoneal
cavity local defense. Am J Nephrol. 26:602–611. 2006. View Article : Google Scholar
|
|
12
|
Bozkurt D, Taskin H, Sezak M, Biçak S, Sen
S, Ok E and Duman S: Rosiglitazone, a peroxisome
proliferator-activated receptor agonist, improves peritoneal
alterations resulting from an encapsulated peritoneal sclerosis
model. Adv Perit Dial. 24:32–38. 2008.
|
|
13
|
Yao Q, Pawlaczyk K, Ayala ER, Kuzlan M,
Styszynski A, Breborowicz A, Heimburger O, Qian J, Stenvinkel P,
Axelsson J and Lindholm B: Peroxisome proliferator-activated
receptor-gamma agonists diminish peritoneal functional and
morphological changes induced by bioincompatible peritoneal
dialysis solution. Blood Purif. 24:575–582. 2006. View Article : Google Scholar
|
|
14
|
Hjelle JT, Golinska BT, Waters DC,
Steidley KR, McCarroll DR and Dobbie JW: Isolation and propagation
in vitro of peritoneal mesothelial cells. Perit Dial Int.
9:341–347. 1989.PubMed/NCBI
|
|
15
|
Davies SJ, Phillips L, Griffiths AM,
Russell LH, Naish PF and Russell GI: What really happens to people
on long-term peritoneal dialysis? Kidney Int. 54:2207–2217. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ha H and Lee HB: Effect of high glucose on
peritoneal mesothelial cell biology. Perit Dial Int. 20(Suppl 2):
S15–S18. 2000.PubMed/NCBI
|
|
17
|
Devuyst O, Topley N and Williams JD:
Morphological and functional changes in the dialysed peritoneal
cavity: impact of more biocompatible solutions. Nephrol Dial
Transplant. 17(Suppl 3): 12–15. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jorres A, Williams JD and Topley N:
Peritoneal dialysis solution biocompatibility: inhibitory
mechanisms and recent studies with bicarbonate-buffered solutions.
Periton Dial Int. 17:S42–S46. 1997.
|
|
19
|
Huang Y, Haraguchi M, Lawrence DA, Border
WA, Yu L and Noble NA: A mutant, noninhibitory plasminogen
activator inhibitor type 1 decreases matrix accumulation in
experimental glomerulonephritis. J Clin Invest. 112:379–388. 2003.
View Article : Google Scholar
|
|
20
|
Higuchi C, Tanihata Y, Nishimura H, Naito
T and Sanaka T: Effects of glucose and plasminogen activator
inhibitor-1 on collagen metabolism in the peritoneum. Ther Apher
Dial. 9:173–181. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Isshiki K, Haneda M, Koya D, Maeda S,
Sugimoto T and Kikkawa R: Thiazolidinedione compounds ameliorate
glomerular dysfunction independent of their insulin-sensitizing
action in diabetic rats. Diabetes. 49:1022–1032. 2000. View Article : Google Scholar
|
|
22
|
Pelzer T, Jazbutyte V, Arias-Loza PA,
Segerer S, Lichtenwald M, Law MP, Schäfers M, Ertl G and Neyses L:
Pioglitazone reverses down-regulation of cardiac PPARgamma
expression in Zucker diabetic fatty rats. Biochem Biophys Res
Commun. 329:726–732. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yuan X, Zhang Z, Gong K, Zhao P, Qin J and
Liu N: Inhibition of reactive oxygen species/extracellular
signal-regulated kinases pathway by pioglitazone attenuates
advanced glycation end products-induced proliferation of vascular
smooth muscle cells in rats. Biol Pharm Bull. 34:618–623. 2011.
View Article : Google Scholar
|
|
24
|
Palakurthi SS, Aktas H, Grubissich LM,
Mortensen RM and Halperin JA: Anticancer effect of
thiazolidinediones are independent of peroxisome
proliferator-activated receptor gamma and mediated by inhibition of
translation initiation. Cancer Res. 61:6213–6218. 2001.PubMed/NCBI
|
|
25
|
Galli A, Crabb DW, Ceni E, Salzano R,
Mello T, Svegliati-Baroni G, Ridolfi F, Trozzi L, Surrenti C and
Casini A: Antidiabetic thiazolidinediones inhibit collagen
synthesis and hepatic stellate cell activation in vivo and in
vitro. Gastroenterology. 122:1924–1940. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bowie A and O’Neill LA: Oxidative stress
and nuclear factor-kappaB activation: a reassessment of the
evidence in the light of recent discoveries. Biochem Pharmacol.
59:13–23. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen F, Castranova V and Shi X: New
insights into the role of nuclear factor-kappaB in cell growth
regulation. Am J Pathol. 159:387–397. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Henkel T, Machleidt T, Alkalay I, Krönke
M, Ben-Neriah Y and Baeuerle PA: Rapid proteolysis of I kappa
B-alpha is necessary for activation of transcription factor
NF-kappa B. Nature. 365:182–185. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mohamed AK, Bierhaus A, Schiekofer S,
Tritschler H, Ziegler R and Nawroth PP: The role of oxidative
stress and NF-kappaB activation in late diabetic complications.
Biofactors. 10:157–167. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nishio Y, Kashiwagi A, Taki H, Shinozaki
K, Maeno Y, Kojima H, Maegawa H, Haneda M, Hidaka H, Yasuda H, et
al: Altered activities of transcription factors and their related
gene expression in cardiac tissues of diabetic rats. Diabetes.
47:1318–1325. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chinenov Y and Kerppola TK: Close
encounters of many kinds: Fos-Jun interactions that mediate
transcription regulatory specificity. Oncogene. 20:2438–2452. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shaulian E and Karin M: AP-1 in cell
proliferation and survival. Oncogene. 20:2390–2400. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ahn JD, Morishita R, Kaneda Y, Lee KU,
Park JY, Jeon YJ, Song HS and Lee IK: Transcription factor decoy
for activator protein-1 (AP-1) inhibits high glucose-and
angiotensin II-induced type 1 plasminogen activator inhibitor
(PAI-1) gene expression in cultured human vascular smooth muscle
cells. Diabetologia. 44:713–720. 2001. View Article : Google Scholar
|
|
34
|
Jeong IK, Oh da H, Park SJ, Kang JH, Kim
S, Lee MS, Kim MJ, Hwang YC, Ahn KJ, Chung HY, et al: Inhibition of
NF-κB prevents high glucose-induced proliferation and plasminogen
activator inhibitor-1 expression in vascular smooth muscle cells.
Exp Mol Med. 43:684–692. 2011.
|
|
35
|
Chen S, Khan ZA, Cukiernik M and
Chakrabarti S: Differential activation of NF-kappa B and AP-1 in
increased fibronectin synthesis in target organs of diabetic
complications. Am J Physiol Endocrinol Metab. 284:E1089–E1097.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen J and Mehta JL: Angiotensin
II-mediated oxidative stress and procollagen-1 expression in
cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J
Physiol Heart Circ Physiol. 291:H1738–H1745. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen S, Mukherjee S, Chakraborty C and
Chakrabarti S: High glucose-induced, endothelin-dependent
fibronectin synthesis is mediated via NF-kappa B and AP-1. Am J
Physiol Cell Physiol. 284:C263–C272. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Arnold R and König W:
Peroxisome-proliferator-activated receptor-gamma agonists inhibit
the release of proinflammatory cytokines from RSV-infected
epithelial cells. Virology. 346:427–439. 2006. View Article : Google Scholar
|
|
39
|
Wang N, Verna L, Chen NG, Chen J, Li H,
Forman BM and Stemerman MB: Constitutive activation of peroxisome
proliferator-activated receptor-gamma suppresses pro-inflammatory
adhesion molecules in human vascular endothelial cells. J Biol
Chem. 277:34176–34181. 2002. View Article : Google Scholar
|
